# BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

## Overview

<b>2024/04/26</b> 08:10:06					
<b>Price</b> <b>7.804</b> EUR					
Difference	0	-1.08% (-0.09)			


General attributes	
ISIN	CA0717341071
Symbol	ВНС
Exchange	Duesseldorf
Currency	EUR
Sector	Other
Security type	Stock
Market cap (m)	2,967 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	7.804 EUR
High	7.804 EUR
Low	7.804 EUR
Close (prev. day)	7.889 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	3
Last size	0

Futures and Options	
Related Futures	15
Related Options	-

### **PDF Downloads**

Company report: BAUSCH HEALTH COMPANIES INC.



Information about previous performance does not guarantee future performance. **Source:** FactSet

### **Recent research**

Œ,

on sector			
Date		Headline	Download
2024/04/26	80. 128 821 138	Global Equity Ratings	
2024/04/03	60. L26 271 170	Global Equity Ratings	
2024/03/13	801   826 821   100	Global Equity Ratings	
2024/02/22	60. L26 271 170	Global Equity Ratings	
2024/02/14	8.   28  21   18	Global Equity Ratings	




# **Details**

<b>2024/04/26</b> 08:10:06					
Price					
<b>7.804</b> EUR					
Difference	0	-1.08% (-0.09)			

General attributes					
ISIN	CA0717341071				
Symbol	ВНС				
Exchange	Duesseldorf				
Currency	EUR				
Sector	Other				
Security type	Stock				
Market cap (m)	2,967 EUR				
Benchmark	S&P/TSX 60 INDEX				

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	7.804 EUR
High	7.804 EUR
Low	7.804 EUR
Close (prev. day)	7.889 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	3
Last size	0

Performance and Risk						
	6m 1Y 3Y					
Perf (%)	+23.42%	+23.79%	-68.93%			
Perf (abs.)	+1.48	+1.50	-17.32			
Beta	1.91	1.25	1.80			
Volatility	39.82	60.51	73.90			



Information about previous performance does not guarantee future performance.  $\textbf{Source:} \ \ \textbf{FactSet}$ 

Price data	
Ø price 5 days   Ø volume 5 days (pcs.)	7.899 EUR (0)
Ø price 30 days   Ø volume 30 days (pcs.)	8.541 EUR (19)
Ø price 100 days   Ø volume 100 days (pcs.)	7.798 EUR (6)
Ø price 250 days   Ø volume 250 days (pcs.)	7.429 EUR (2)
YTD High   date	9.790 EUR (2024/04/02)
YTD Low   date	7.006 EUR (2024/01/03)
52 Weeks High   date	9.790 EUR (2024/04/02)
52 Weeks Low   date	5.138 EUR (2023/05/08)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/04/ 26	22:26	8.145 EUR	0.01	3
Toronto Stock Exchange	2024/04/ 26	22:00	11.92 CAD	2.20	1,296
Stuttgart	2024/04/ 26	17:47	8.173 EUR	0.00	9
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/04/	22:00	8.71 USD	18.16	10,974



	26				
Munich	2024/04/ 26	08:03	7.976 EUR	0.00	2
Frankfurt	2024/04/ 26	08:13	7.818 EUR	0.00	2
Duesseldorf	2024/04/ 26	08:10	7.804 EUR	0.00	3
Berlin	2024/04/ 26	08:04	7.819 EUR	0.00	2



# Company profile

**Company Logo** 

## **BAUSCH** Health

#### **Contact Details**

BAUSCH HEALTH COS. INC.

\_ \_

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

#### **PDF Downloads**

Company report: BAUSCH HEALTH COMPANIES INC.

đ.

#### **Company Profile**

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board	
Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee
Seana Carson	Member of Executive Committee
Tom Vadaketh	Member of Executive

Committee

Board of directors	
John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Russel Robertson	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board
Thomas Ross	Member of Supervisory Board

